All In Biotech

Drug Trial Radar · NCT05265052

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

177

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
3D MedicinesIndustry
Sponsor type
Industry
First posted
Mar 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Conditions

  • Cancer Pain

Interventions

  • 3D1002 (50 mg)(Phase IIa)Drug

    1 tablet of 3D1002 per oral dose

  • 3D1002 (100 mg)(Phase IIa)Drug

    2 tablets of 3D1002 per oral dose

  • 3D1002 (150 mg)(Phase IIa)Drug

    3 tablets of 3D1002 per oral dose

  • 3D1002 monotherapy (Phase IIb)Drug

    3D1002 is administered at recommended dose with mimic OxyContin tablets.

  • OxyContin monotherapy (Phase IIb)Drug

    OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.

  • 3D1002 + OxyContin (Phase IIb)Drug

    3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of pain intensity difference in the Numeric Rating Scale (NRS) within 14 days after the first study drug treatment (SPID14)Time frame: 1 to 14 days after receiving study treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.